Horizon Provides Assurances That Tepezza Sales Are Set To Soar

Guidance Maintained For 30% Growth In 2022

Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights.

Red-tailed Hawk flying over the mountains with sky background — Horizon expects more than 30% Tepezza sales growth in 2022 • Source: Shutterstock

COVID-19 continues to put pressure on Horizon Therapeutics plc’s Tepezza (teprotumumab), which quickly generated blockbuster-level sales despite its pandemic-era launch but experienced a sequential decline in sales during the first quarter. However, while the Omicron variant affected Q1 sales, the company is maintaining its guidance for mid-30% growth in 2022 and further investing in its commercial team to capitalize on recent thyroid eye disease (TED) market insights.

Horizon generated impressive results for Tepezza (teprotumumab) to date with $820m in 2020 sales after its launch in February of...